# Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Study · id `cardio:ct-nct05030428` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05030428](<https://clinicaltrials.gov/study/NCT05030428>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05030428

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 17004 participants.

## Technical summary

Registry record NCT05030428. Randomized; double masking; primary purpose treatment. Start 2021-11-23 (actual); primary completion 2027-05-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 17004 participants (enrolled count; ClinicalTrials.gov record NCT05030428, source copy `cardio:ctgov-nct05030428-2026-11-16`, retrieved 2026-11-18)
- Started: 2021-11-23 (actual) (ClinicalTrials.gov record NCT05030428, source copy `cardio:ctgov-nct05030428-2026-11-16`, retrieved 2026-11-18)
- Primary completion: 2027-05-10 (anticipated) (ClinicalTrials.gov record NCT05030428, source copy `cardio:ctgov-nct05030428-2026-11-16`, retrieved 2026-11-18)
- Completion: 2027-05-10 (anticipated) (ClinicalTrials.gov record NCT05030428, source copy `cardio:ctgov-nct05030428-2026-11-16`, retrieved 2026-11-18)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Croatia; Czechia; Denmark; Estonia; Finland; France; Greece; Hungary; Iceland; India; Israel; Italy; Japan; Kenya; Latvia; Lithuania; Malaysia; Mauritius; Mexico; Netherlands; New Zealand; Norway; Philippines; Poland; Portugal; Puerto Rico; Romania; Russia; Serbia; Singapore; Slovakia; Slovenia; South Africa; South Korea; Spain; Sweden; Taiwan; Thailand; Türkiye (ClinicalTrials.gov record NCT05030428, source copy `cardio:ctgov-nct05030428-2026-11-16`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05030428-2026-11-16`, retrieved 2026-11-18)

## The registry's words

- Brief title: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
- Acronym: VICTORION-2P
- Condition: Atherosclerotic Cardiovascular Disease
- Intervention (Drug): Inclisiran sodium 300 mg
- Intervention (Drug): Placebo
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Inclisiran (`cardio:inclisiran`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 1ed419ef8e4656e54aebf474ea64745b0be336dc82f822923e52c8aa82fb5ad0
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
